Last reviewed · How we verify
NCT06879925: QG-PASC
Physiological and QoL Benefits of Qi-Gong in Post-acute Sequelae of Covid-19
NA trial testing QI-GONG and control in PASC Post Acute Sequelae of COVID 19 in 80 participants. Currently enrolling.
7 April 2025
Quick facts
| Lead sponsor | POCHIWU |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 80 |
| Start date | 2 December 2024 |
| Primary completion | 7 April 2025 |
| Estimated completion | 7 April 2025 |
| Sites | 2 locations across Taiwan |
Drugs / interventions tested
- QI-GONG and control
Conditions studied
- PASC Post Acute Sequelae of COVID 19 — all drugs for PASC Post Acute Sequelae of COVID 19 →
Sponsor
POCHIWU
Who can join
Adults 20 to 100, any sex, with PASC Post Acute Sequelae of COVID 19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to determine whether Qi-Gong can improve physiological function and quality of life (QoL) in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC). Study Objectives: To assess whether Qi-Gong improves physiological function in individuals with PASC. To evaluate whether Qi-Gong enhances quality of life in individuals with PASC. Study Design: If a comparison group is included, researchers will compare Qi-Gong with standard care to assess its effectiveness. Participant Involvement: Practice Qi-Gong three times per week for three months. Record physiological data monthly.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06879925
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for PASC Post Acute Sequelae of COVID 19
Currently open trials in the same condition.
- NCT07278206 — Brain Stimulation in Long COVID · NA · recruiting
- NCT07278388 — Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2 · NA · recruiting
- NCT06940609 — Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation · Phase 2 · recruiting
- NCT06586398 — A Pilot rTMS Trial for Neuropsychiatric Symptoms of Long-COVID · NA · active not recruiting
- NCT05040659 — Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06879925 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by POCHIWU
- Last refreshed: 17 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06879925.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing